Clinical trials
Mild Alzheimer Disease clinical trials
Below are recruiting mild alzheimer disease clinical trials, each written for real people, not researchers. We’re tracking 305 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05887674Recruiting
Non-drug memory program for early Alzheimer’s and memory loss
This trial studies a non-medication (non-drug) program to improve memory and daily thinking in people with mild cognitive impairment or mild Alzheimer’s disease. It may help by supporting brain function and monitoring symptoms over time.
Shanghai, Shanghai MunicipalityAges 60–90 - NCT07604896RecruitingPhase 4
Lecanemab for early Alzheimer's disease with amyloid buildup
This trial tests lecanemab, an infusion medicine that targets amyloid protein buildup in the brain, in people with mild cognitive impairment or mild Alzheimer's disease. Researchers will track how well it works and study how it affects your body's proteins using advanced lab tests.
Wenzhou, ZhejiangAges 50–90 - NCT06181513RecruitingEarly Phase 1
Probiotics for mild Alzheimer's disease
This study tests whether daily probiotics (beneficial bacteria) can help people with mild Alzheimer's disease. It's an early-phase trial to see if probiotics are safe and might improve thinking and memory.
NicosiaAges 65–85 - NCT07570719Recruiting
Community screening for early Alzheimer's disease signs
This study screens people aged 60–80 for early signs of Alzheimer's disease in a community setting. Researchers will ask you questions and may perform brain imaging to understand who might benefit from early detection and treatment.
Shanghai, Shanghai MunicipalityAges 60–80 - NCT07553338RecruitingPhase 2
Leronlimab Safety and Brain Inflammation in Alzheimer's
This study tests whether a drug called leronlimab is safe and can reduce inflammation in the brains of people with mild-to-moderate Alzheimer's disease or memory problems. Researchers will use special brain scans to see if the drug affects inflammation.
New York, New YorkAges 50 years+ - NCT07512362RecruitingPhase 2
Stem cells and antibodies for early Alzheimer's disease
This study tests whether human stem cells, combined with your existing Alzheimer's medication (Leqembi or Kisunla), can help slow memory loss and improve daily functioning in people with mild cognitive impairment or early Alzheimer's. You would receive a stem cell infusion as an add-on to your current treatment.
Miami, FloridaAges 55–90 - NCT06702124RecruitingPhase 3
Rotigotine patch with rivastigmine for mild to moderate Alzheimer's
This trial tests if adding a rotigotine patch to your usual rivastigmine treatment can help with symptoms of Alzheimer's. It is for people with mild to moderate Alzheimer's who have been stable on rivastigmine for at least 3 months.
Rome, ItalyAges 50–85 - NCT06792877Recruiting
Mindfulness for thinking in early Alzheimer's
This study tests if mindfulness training can help protect thinking and memory in early-stage Alzheimer's disease. It compares mindfulness to other activities to see if it slows down memory loss.
Boston, MassachusettsAges 50–100 - NCT07457125RecruitingPhase 1/Phase 2
Exosome therapy for mild to moderate Alzheimer's disease
This trial tests a new drug made from stem cell exosomes (CB-Exo-A600) to see if it can help people with mild to moderate Alzheimer's disease. It aims to slow down symptoms and improve quality of life.
BeijingAges 50 years+ - NCT07367815RecruitingPhase 1/Phase 2
Stem cells from fat tissue for Alzheimer's disease
This trial tests whether stem cells from donated fat tissue can help people with mild to moderate Alzheimer's disease. It combines infusions of these cells with standard care, and includes brain scans and memory tests to see if the treatment is safe and effective.
ToulouseAges 50–85 - NCT05413655RecruitingPhase 2
Oral drug for mild Alzheimer’s disease symptoms
This Phase 2 trial tests an oral medicine (EX039) to see if it can help people with mild Alzheimer’s disease. It focuses on slowing or improving thinking and memory problems over time.
TaipeiAges 50–80 - NCT06850597RecruitingPhase 2
Testing dimethyl fumarate for early Alzheimer's disease
This study tests a drug called dimethyl fumarate to see if it can help people with early Alzheimer's disease. It may slow down memory loss and thinking problems.
Lodz, Łódź VoivodeshipAges 55–90 - NCT06852352Recruiting
Modified brain lymph surgery for Alzheimer's or Parkinson's
This study tests a new, less invasive surgery to improve lymph drainage from the brain. It may help clear harmful proteins linked to Alzheimer's or Parkinson's disease.
Hangzhou, ZhejiangAges 50–80 - NCT06619613RecruitingPhase 1
Study of CM383 for early Alzheimer's disease
This trial tests a new drug called CM383 in people with mild cognitive impairment or mild Alzheimer's disease. The goal is to see if it can help slow down memory loss.
HefeiAges 50–85 - NCT07262645RecruitingPhase 3
Light therapy for mild Alzheimer's disease
This study tests if a near-infrared light therapy device can help improve memory and thinking in people with mild to moderate Alzheimer's disease. It involves daily treatment sessions with the device, and a study partner must be available to help with treatment.
Beijing, Beijing MunicipalityAges 50–85 - NCT07239310Recruiting
Device to improve memory and thinking in early Alzheimer's
This study tests a device called Neuclare that aims to temporarily boost memory and thinking skills in people with mild cognitive impairment or very early Alzheimer's disease. It could offer a non-drug way to help with daily mental tasks.
Cheonan, Chungcheongnam-doAges 55–90 - NCT07236190RecruitingPhase 2
Testing NPC-1 for people with Alzheimer's signs
This study tests whether a medicine called NPC-1 can help people with mild memory or thinking problems or early-stage Alzheimer's. It looks at a blood marker to see if the treatment may slow down the disease.
Boston, MassachusettsAges 55 years+ - NCT07234695RecruitingPhase 3
Levetiracetam to prevent seizures in adults with Down syndrome and Alzheimer's
This trial tests if levetiracetam, a seizure medication, can prevent seizures in adults with Down syndrome who also have Alzheimer's disease. It aims to help manage a common complication and improve quality of life.
Granada, AndalusiaAges 40 years+ - NCT07169630RecruitingPhase 1
PET scan study for Alzheimer's or mild cognitive impairment
This study uses a special PET scan to look at a brain protein called PDE4 in people with Alzheimer's disease or mild cognitive impairment. It may help researchers understand how this protein is involved in memory and thinking problems.
Bethesda, MarylandAges 50–100 - NCT07154394Recruiting
Heart amyloid and function in Alzheimer's disease
This study examines whether amyloid plaques in the heart affect heart function in people with Alzheimer's disease. It uses brain amyloid PET and MRI scans to explore a potential link.
Essen, North Rhine-WestphaliaAges 18 years+ - NCT07089303Recruiting
Alzheimer's brain imaging study (AD-MINER)
This study uses advanced brain imaging to learn more about Alzheimer's disease. It looks at people with normal memory, mild memory problems, or Alzheimer's dementia to find better ways to diagnose and track the disease.
Beijing, Beijing MunicipalityAges 55–90 - NCT07058688RecruitingPhase 2
Testing a new drug for Alzheimer's (NTRX-07)
This study tests an experimental drug for Alzheimer's called NTRX-07. It aims to see if it can slow memory decline for people with mild to moderate Alzheimer's.
BrnoAges 65–80 - NCT07027072RecruitingPhase 2
Testing KDS2010 for early Alzheimer's memory loss
This study tests a new drug called KDS2010 for people with early Alzheimer's or mild memory loss. It aims to see if the drug can slow thinking and memory decline. You will need a caregiver to help with visits and must have a special brain scan showing amyloid plaques.
Gwangju, GwangjuAges 50–85 - NCT03851523Recruiting
Tracking memory changes in people with early Alzheimer’s symptoms
This study follows people over time to better understand how memory and thinking complaints progress in early Alzheimer’s disease (from “subjective cognitive decline” to mild cognitive problems). It may help researchers understand who is likely to decline and how symptoms change, which could support future treatments.
Barcelona, CataloniaAges 45 years+
Hear when a new Mild Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for mild alzheimer disease?
- Yes. Clin2 currently lists 305 recruiting mild alzheimer disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a mild alzheimer disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a mild alzheimer disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.